Ring Therapeutics Announces Two Late Breaker Presentations at the 30th Annual European Society of Gene & Cell Therapy Conference
Ring to present new data on its Anellogy™ platform The first new class of viral…
Ring to present new data on its Anellogy™ platform The first new class of viral…
Cohort dosing complete in healthy subjects, with the Phase I/II study on track to meet…
Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence…
Expects to announce topline data expected in the November/December timeframe. Enrolled patients had underlying medical…
Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival…
Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at several…
Figure 1. Treatment with pepinemab in combination with KEYTRUDA appears to induce formation of highly…
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the…
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio,…
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 million sBLA for F8…
Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total…
Change in ELF Score at 12 Weeks in INTEGRIS-PSC Change in ELF Score at 12…
– Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key…
Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering…
HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic…
PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology…
WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) — In a major achievement,…